相关实验视频
Updated: Jun 13, 2025

05:17
Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
Published on: April 18, 2025
117
地中海饮食和痴呆症:来自元分析的MRI标志物证据
Xiaojie Wang1, Zhiyao Xin2,3,4, Xiuwen Li2,3,4
1Department of Neurology, Shenzhen Qianhai Shekou Free Trade Zone Hospital, Shenzhen, 518067, Guangdong, China.
European journal of medical research
|January 15, 2025
概括
坚持地中海饮食 (MeDi) 可以减少老年人白质过强度 (WMH). 这一发现表明,MeDi可能是影响大脑健康的可修改因素,并可能降低痴呆风险.
科学领域:
- 神经学 神经学
- 营养科学 营养科学
- 公共卫生 公共卫生
背景情况:
- 痴呆症是一个越来越大的公共卫生挑战,治疗选择有限.
- 饮食是影响大脑健康的潜在可修改因素.
- 地中海饮食 (MeDi) 与痴呆相关的大脑MRI标志物有关,但证据不一致.
研究的目的:
- 系统地审查和元分析MeDi坚持和与痴呆相关的MRI标志物之间的关联.
- 量化MeDi对特定脑成像指标的影响.
主要方法:
- 在PubMed,Embase和Web of Science的系统文献搜索到2024年9月.
- 包括流行病学研究报告MeDi和MRI标记物的效果大小.
- 针对横截面和纵向研究设计的单独元分析.
主要成果:
- 分析了20项研究,共有44,893名参与者.
- 截面分析显示,MeDi与减少白质超强度 (WMH) 之间存在显著的关联.
- 在横截面或纵向分析中,没有发现MeDi与大脑总体积,灰质体积,白质体积或海马体积之间的显著关联.
结论:
- 梅迪坚持可能与老年人WMH降低有关.
- 这表明MeDi在维持大脑健康方面可能发挥作用.
- 需要进一步的研究来探索MeDi作为减少痴呆风险的可修改因素.
相关概念视频
Dementia
107
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
107
Alzheimer's Disease: Overview
452
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
452
Alzheimer's Disease: Treatment
170
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
170

